Key Metrics
Journal Specifications
- PublisherMARY ANN LIEBERT, INC
- LanguageEnglish
- FrequencyBi-monthly
- LanguageEnglish
- FrequencyBi-monthly
- Publication Start Year2011
- Publisher URL
- Website URL
Topics Covered
Year-wise Publication
- 5Y
- 10Y
FAQs
Since when has Nucleic Acid Therapeutics been publishing?
The Nucleic Acid Therapeutics has been publishing since 2011 till date.
How frequently is the Nucleic Acid Therapeutics published?
Nucleic Acid Therapeutics is published Bi-monthly.
Who is the publisher of Nucleic Acid Therapeutics?
The publisher of Nucleic Acid Therapeutics is MARY ANN LIEBERT, INC.
How can I view the journal metrics of Nucleic Acid Therapeutics on editage?
For the Nucleic Acid Therapeutics metrics, please refer to the section above on the page.
What is the eISSN and pISSN number of Nucleic Acid Therapeutics?
The eISSN number is 2159-3345 and pISSN number is 2159-3337 for Nucleic Acid Therapeutics.
What is the focus of this journal?
The journal covers a wide range of topics inlcuding Oligonucleotide, RNA interference, RNA editing, Guide RNA, Exon, Amyloid precursor protein, Antisense oligonucleotides, Minicircle dna, Serum protein, Duchenne muscular dystrophy, Exon skipping, DNA Aptamers, Antisense RNA, Amyloid angiopathy, Type 2 diabetes, Protein splicing, G-quadruplex, RNA Aptamers, Ribosomal protein.
Why is it important to find the right journal for my research?
Choosing the right journal ensures that your research reaches the most relevant audience, thereby maximizing its scholarly impact and contribution to the field.
Can the choice of journal affect my academic career?
Absolutely. Publishing in reputable journals can enhance your academic profile, making you more competitive for grants, tenure, and other professional opportunities.
Is it advisable to target high-impact journals only?
While high-impact journals offer greater visibility, they are often highly competitive. It's essential to balance the journal's impact factor with the likelihood of your work being accepted.